These companies don't typically compete directly with one another, but that might change soon.

The GLP-1 maker’s latest AI investment targets drug discovery and the future of consumer medicine.

Just about every evening when I sit down for dinner and turn on the television, a series of commercials with catchy jingles grabs my attention. It's always the same ads, each promoting a treatment ...

Eli Lilly (NYSE: LLY) stock soared 10% in one trading session this week, sparked by a strong earnings report. And the pharma giant's gains may be far from over. The company has been offering investors ...

The introduction of GLP-1 drugs has revolutionized the way the world looks at weight loss. Taking a shot or a pill to curb one's appetite and lose weight is close to a miracle for those who have long ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the ...